Versartis Inc. (VSAR)

5.96
0.01 0.25
NASDAQ : Health Technology
Prev Close 5.97
Open 5.93
Day Low/High 5.93 / 6.00
52 Wk Low/High 3.07 / 13.80
Volume 1.95K
Avg Volume 207.40K
Exchange NASDAQ
Shares Outstanding 36.24M
Market Cap 43.13M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
VSAR: Insiders vs. Shorts

VSAR: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/29/2016 settlement date, and Versartis Inc is one of the most shorted stocks of the Russell 3000, based on 5.85 "days to cover" versus the median component at 4.92. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Versartis' VRS-317 6-Month Data Published In The Journal Of Clinical Endocrinology & Metabolism

Versartis' VRS-317 6-Month Data Published In The Journal Of Clinical Endocrinology & Metabolism

Results Show Positive Safety and Efficacy Data With Similar Outcomes Across Three Dosing Regimens

VSAR: Insiders vs. Shorts

VSAR: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 10/30/2015 settlement date, and Versartis Inc is one of the most shorted stocks of the Russell 3000, based on 11.77 "days to cover" versus the median component at 5.62. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting

Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study At Late-Breaker Session At ESPE Annual Meeting

Data From Ongoing Pediatric Extension Study Confirms Dose Used in VELOCITY Phase 3 Trial Provides Stable Second Year Growth Rates and Similar Safety Profile to Daily Treatment

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study Of Somavaratan In GHD Children

Late-Breaking Data Show 3.5 mg/kg Twice-Monthly Dosing Increased Mean Peak IGF-I SDS and Stabilized 12 to 18 Month Mean Height Velocity While Maintaining Safety Profile

Versartis To Host Investor Symposium Featuring Global Opinion Leaders In Pediatric Human Growth Hormone Deficiency

Versartis To Host Investor Symposium Featuring Global Opinion Leaders In Pediatric Human Growth Hormone Deficiency

International Panel of Pediatric Endocrinologists to Provide Perspectives on GHD

Versartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & Losers

Versartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & Losers

Shares of biotech Versartis and online provider of insurance products eHealth rose sharply, but network solutions company Silicom saw a big drop-off.

Market News: Aetna, Versartis, Agile Therapeutics

Market News: Aetna, Versartis, Agile Therapeutics

The stock markets in the United States declined amid fears that Greece is headed towards an exit from the Eurozone. The equity markets were also negatively impacted by the decline in oil prices. Sign ...

10 Worst Biotech Stocks in the NASDAQ

10 Worst Biotech Stocks in the NASDAQ

Some biotech stocks way underperformed in this red-hot sector.

Versartis Becomes Oversold (VSAR)

Versartis Becomes Oversold (VSAR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Versartis Provides Update On Clinical Programs And Reports First Quarter 2015 Financial Results

Versartis Provides Update On Clinical Programs And Reports First Quarter 2015 Financial Results

Conference Call and Webcast Scheduled for Today at 5:00 p.m. ET

Versartis Appoints Jay Shepard As President And Chief Executive Officer

Versartis Appoints Jay Shepard As President And Chief Executive Officer

Jeffrey L. Cleland, PhD, Assumes Role as Senior Scientific Advisor

Versartis Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting

Versartis Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting

Data From Ongoing Pediatric Extension Study of Long-acting rhGH Presented Today at 1:00 p.m. PT Poster Session